EUR/USD 1.16874
-0.109%
Gold 3356.20
0.972%
Oil 67.491
2.447%
USD/JPY 147.368
0.758%
GBP/USD 1.34968
-0.596%
GBP/JPY 198.904
0.188%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
Former Federal Reserve Board Governor Walsh: (Commenting on the renovation of the Federal Reserve building) Its shocking.Former Federal Reserve Board member Walsh: The Fed should cut interest rates now.July 13, White House economic adviser Hassett said on Sunday that US President Trump has the power to fire Federal Reserve Chairman Powell if there is evidence to support it, adding that the Fed "bears a lot of responsibility" for the over-budget renovation of its Washington headquarters. Hassett said any decision by Trump to try to fire Powell would depend largely on the Feds answer to the headquarters renovation issue. White House Budget Office Director Watt last week slammed Powell for "lying" about the renovation of the Federal Reserve building. Trump has repeatedly said that Powell should resign because he did not lower interest rates.International Atomic Energy Agency: Starting at 10 p.m. local time, large numbers of artillery shells were fired repeatedly for about an hour, which is unusual.White House economic adviser Hassett said Trump has the authority to take action if there is reason to fire Powell.

U.S. Restricts Use of J&J's COVID Vaccine Due to Risk of Blood Clots

Charlie Brooks

May 06, 2022 09:38

J2.png


The US Food and Drug Administration said on Thursday that it will restrict adult use of Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccination owing to the danger of a rare blood clotting condition, the latest setback for the injection that has been supplanted by competitors.


The J&J shot, which was cleared for adult use in the United States in February 2021, may be used in situations when permitted or approved COVID-19 vaccinations are unavailable or if an user is averse to receiving the other two doses, the Food and Drug Administration said.


J&J is one of three vaccinations that are now in use in the United States. The remaining two are from Moderna (NASDAQ:MRNA) and Pfizer, respectively (NYSE:PFE).


The vaccine manufacturer said that it has amended the COVID-19 vaccination information sheet for the United States to include a warning regarding the risk of thrombosis associated with thrombocytopenia syndrome (TTS), an uncommon but potentially fatal illness.


In high-income nations, use of the J&J shot has been limited, owing to reports of rare, possibly fatal blood clots, manufacturing difficulties, including an unintentional component mix-up by a contract manufacturer, and doubts about effectiveness.


The manufacturer revised its projection for COVID-19 vaccine sales last month, citing a supply glut.


TTS, which is characterized by blood clots and a low platelet count, has previously been documented in recipients of the J&J vaccination.


The FDA changed the information sheet for the J&J vaccine in January to reflect the risk of immune thrombocytopenia, after months of similar action by the European Union's medicines authority.


The FDA stated Thursday that after conducting a study into reported instances, the risk of TTS justified restricting the use of the single-dose injection.


In December, the US Centers for Disease Control and Prevention suggested that Americans take mRNA doses from Pfizer or Moderna rather than J&J's vaccination owing to the possibility of blood clotting.


According to the CDC, about 18.7 million Americans got a J&J COVID-19 injection, compared to 217.5 million who received the Moderna vaccination and 340.6 million who received the Pfizer shot.

Suggestion